EMA Recommends Rezurock for Chronic Graft-Versus-Host Disease

Why It Matters

Rezurock provides the first ROCK2‑targeted oral option for cGVHD, potentially improving outcomes for patients who have exhausted standard immunosuppressants. Its conditional approval could accelerate market entry and set a precedent for expedited pathways in rare, high‑unmet‑need indications.

Key Takeaways

• EMA recommends conditional approval for Rezurock in cGVHD patients
• 73% response rate; 44% maintain response at six months
• Targets ROCK2, offering oral once‑daily therapy
• Addresses unmet need after multiple failed lines of treatment
• Prophylactic combo cuts cGVHD incidence to 3% versus 33%

Pulse Analysis

Chronic graft‑versus‑host disease remains one of the most debilitating complications after allogeneic stem‑cell transplantation, affecting up to 70 % of adult recipients and a significant fraction of pediatric patients. The disease manifests as persistent immune attack on host tissues, leading to organ fibrosis, severe infections, and reduced survival. Existing therapeutic armamentarium is dominated by high‑dose corticosteroids and broad‑spectrum immunosuppressants, which provide only transient control and carry risks of cytopenias, opportunistic infections, and secondary malignancies. Consequently, a sizable proportion of patients require multiple lines of therapy, underscoring a critical unmet medical need.

Rezurock (belumosudil) distinguishes itself by inhibiting ROCK2, a kinase that modulates fibro‑fibrotic signaling and T‑cell differentiation, enabling an oral once‑daily regimen that directly targets the pathogenic axis of cGVHD. In the pivotal open‑label study, 73 % of heavily pre‑treated patients responded within six months, with nearly half preserving that benefit at the same time point and a modest 5 % achieving complete remission. The EMA’s conditional marketing authorization reflects a regulatory willingness to expedite access for therapies addressing rare, high‑unmet‑need diseases, while obligating Sanofi to complete a confirmatory randomized trial. This pathway reduces time‑to‑market and may influence future development strategies for niche immunomodulators.

Beyond Rezurock, emerging prophylactic regimens that combine sirolimus, cyclosporine and post‑transplant cyclophosphamide have demonstrated a drop in moderate‑to‑severe cGVHD incidence from 33 % to roughly 3 %, reshaping transplant protocols. However, the intensified immunosuppression raises infection concerns, highlighting the delicate balance manufacturers must achieve between efficacy and safety. As European member states negotiate pricing, the drug’s orphan‑medicine status and conditional approval may command premium reimbursement, while competitors watch for data that could spur similar ROCK2‑targeted pipelines. The combined therapeutic advances promise to improve long‑term survival and quality of life for transplant survivors.